Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study is a Phase II randomized, open label, controlled, multicenter study to access the
effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy
for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including
patients previous treated with a PARP inhibitor).